header logo image header logo text
Downloads Login
Research
General Information
ZIRC
ZFIN ID: ZDB-IMAGE-090331-9
Figures for Nelson et al., 2009

Figure Caption/Comments:

Fig. 7 Efficacy and perdurance of rx1 and rx2 splice site-targeting MOs in embryos treated at the 1–2-cell stage (“0 hpf”) and at 44.5 hpf. The presence of large amplicons (upper row) indicates aberrant splicing. Lanes 1 and 2, embryos injected with rx1 or rx2-targeted MOs at 0 hpf and extracted at 30 hpf; lanes 3 and 4, embryos injected with the 5-mispair control MO at 0 hpf and extracted at 53 hpf; lanes 5 and 6, embryos injected with rx1 or rx2-targeted MOs at 0 hpf and extracted at 53 hpf; lanes 7 and 8, embryos injected with rx-1 or rx2-targeted MOs at 44.5 hpf and extracted at 53 hpf; lanes 9–12, embryos injected with rx1- or rx2-targeted MOs at 0 hpf (lanes 9 and 10) or at 44.5 hpf (lanes 11 and 12) and extracted at 60 hpf.

Figure Data:
Acknowledgments:
ZFIN wishes to thank the journal for permission to reproduce figures from this article. Please note that this material may be protected by copyright.